{
  "abstract": "Background: Early assessment during first-line immune-combination therapy for unresectable hepatocellular carcinoma (HCC) must consider both antitumor activity and hepatic tolerance. Existing integrated approaches have paired early AFP variation with baseline liver reserve, but they do not directly ask whether hepatic reserve is preserved or deteriorates over the same early treatment interval. We investigated whether early alpha-fetoprotein (AFP) response and change in modified albumin-bilirubin (ALBI) grade define clinically interpretable response-tolerance phenotypes.\n\nMethods: This retrospective landmark cohort included AFP-evaluable patients with unresectable HCC who received first-line immune-combination therapy. Follow-up for the primary analysis began 70 days after treatment initiation. AFP response was defined as a landmark-to-baseline ratio of 0.80 or lower among patients with baseline AFP of at least 20 ng/mL; modified ALBI deterioration was defined as worsening by at least one category. Patients were classified as concordant favorable, response-liver vulnerability, nonresponse-liver preserved, or concordant failure. The primary endpoint was progression-free survival (PFS).\n\nResults: Of 286 treated patients, 68 (23.8%) had baseline AFP below 20 ng/mL and were not AFP-evaluable; 166 patients entered the primary day-70 cohort. The four phenotypes included 58, 36, 43, and 29 patients, respectively. Relative to concordant favorable, concordant failure had the strongest adjusted association with shorter PFS (hazard ratio [HR] 2.85, 95% confidence interval [CI] 1.63–4.99; P <0.001), followed by nonresponse-liver preserved (HR 1.69, 95% CI 1.02–2.79; P = 0.040). The estimate for response-liver vulnerability was smaller and imprecise (HR 1.49, 95% CI 0.89–2.49; P = 0.130). The combined non-favorable group was associated with shorter PFS (HR 1.79, 95% CI 1.18–2.72; P = 0.006). The hepatic-decompensation estimate was imprecise after parsimonious adjustment (odds ratio 2.42, 95% CI 0.90–6.50; P = 0.081). Overall survival (OS) estimates were also imprecise; the largest point estimate was observed for concordant failure (HR 2.09, 95% CI 1.00–4.38; P = 0.050).\n\nConclusion: Early AFP-ALBI discordance distinguished different patterns of tumor-marker response and hepatic tolerance during immune-combination therapy. In AFP-evaluable patients with an ambiguous first assessment, a non-favorable biochemical pattern may support earlier multimodal reassessment of tumor status, liver function, and treatment feasibility, but it should not be used as a stand-alone rule for changing therapy.",
  "abstract_shown": true,
  "affiliations": [
    "Department of Hepatobiliary and Pancreatic Surgery, Affiliated Hospital of Nantong University, Nantong University Medical School"
  ],
  "article_type": "research article",
  "arxiv": null,
  "author_total": 6,
  "authors": [
    {
      "affs": [
        0
      ],
      "name": "Haitao Wu"
    },
    {
      "affs": [
        0
      ],
      "name": "Pengju Tang"
    },
    {
      "affs": [
        0
      ],
      "name": "Jinbo Gong"
    },
    {
      "affs": [
        0
      ],
      "name": "Xintao Shi"
    },
    {
      "affs": [
        0
      ],
      "name": "Yiming Zhao"
    },
    {
      "affs": [
        0
      ],
      "name": "Zhong Chen"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/6a4jh31ax27kf.bib",
  "cited_by": 0,
  "doi": "10.3389/fonc.2026.1954746",
  "fulltext_url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13724454/?tool=EBI",
  "id": "6a4jh31ax27kf",
  "issns": [
    "2234-943X"
  ],
  "landing_url": "https://www.frontiersin.org/articles/10.3389/fonc.2026.1954746/full",
  "language": "eng",
  "licence": "CC-BY-4.0",
  "licence_label": "CC BY 4.0",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "heading",
      "Original Research"
    ],
    [
      "openalex",
      "2721|Hepatocellular Carcinoma Treatment and Prognosis"
    ]
  ],
  "openalex": "W7222935761",
  "pdf_url": "https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2026.1954746/pdf",
  "pmcid": "PMC13724454",
  "pmid": "42973518",
  "published": "2026-10-19",
  "publisher": "Frontiers Media SA",
  "ris": "https://research.draconitic.com/paper/6a4jh31ax27kf.ris",
  "sources": [
    {
      "first_seen": "2026-10-30T12:20:13Z",
      "native_id": "10.3389/fonc.2026.1954746",
      "source": "crossref",
      "url": "https://www.frontiersin.org/articles/10.3389/fonc.2026.1954746/full"
    },
    {
      "first_seen": "2026-11-03T15:20:51Z",
      "native_id": "PMC:PMC13724454",
      "source": "europepmc",
      "url": "https://europepmc.org/article/PMC/PMC13724454"
    },
    {
      "first_seen": "2026-11-04T12:23:01Z",
      "native_id": "PMC13724454",
      "source": "pmc",
      "url": "https://doi.org/10.3389/fonc.2026.1954746"
    },
    {
      "first_seen": "2026-11-04T15:20:48Z",
      "native_id": "MED:42973518",
      "source": "europepmc",
      "url": "https://europepmc.org/article/MED/42973518"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "issn:2234-943X",
      "subfield": "oncology"
    }
  ],
  "title": "Early discordance between alpha-fetoprotein response and albumin-bilirubin deterioration refines response assessment in unresectable hepatocellular carcinoma receiving first-line immune-combination therapy: a real-world landmark cohort study",
  "title_text": "Early discordance between alpha-fetoprotein response and albumin-bilirubin deterioration refines response assessment in unresectable hepatocellular carcinoma receiving first-line immune-combination therapy: a real-world landmark cohort study",
  "type": "peer-reviewed",
  "updated_at": "2026-11-05T12:21:12Z",
  "url": "https://research.draconitic.com/paper/6a4jh31ax27kf",
  "venue": "Frontiers in Oncology",
  "versions": []
}